ARA-290 vs Livagen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- Half-Life
- ~2–4 hours (SC administration)
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Stacks With
- —
- —